Regorafenib

Spezifikationen

755037-03-7CAS-Nummer

815-051-1EG-Nummer

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamideIUPAC-Name

C21H15ClF4N4O3Chemische Formel

482.8 g/molMolekulargewicht

Regorafenib; 755037-03-7; BAY 73-4506; Stivarga; Regorafenibum; BAY73-4506; BAY-73-4506; REGORAFENIB ANHYDROUS; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; 24T2A1DOYB; Bay-734506; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-734506 monohydrate; BAY 73-4506 monohydrate; CHEBI:68647; DTXSID60226441; BAY-73-4506 MONOHYDRATE; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide; 4-(4-((4-chloro-3-(trifluoromethyl)phenyl)carbamoylamino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide; RefChem:57911; DTXCID60148932; L01XE21; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)-3-fluorophenoxy)-N-methyl-, hydrate (1:1); MGN125FS9D; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; Regorafenib (BAY 73-4506); C21H15ClF4N4O3; MFCD16038047; 2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-; CHEMBL1946170; 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide; Stivarga (TN); 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluoro-phenoxy]-N-methyl-pyridine-2-carboxamide; Regorafenib [INN]; Regorafenib [USAN:INN]; UNII-24T2A1DOYB; Regorafenib (Standard); A1JCR; REGORAFENIB [MI]; Regorafenib (USAN/INN); REGORAFENIB [VANDF]; BAY73-4506 hydrochloride; REGORAFENIB [WHO-DD]; MLS006010303; Regorafenib crystalline form I; SCHEMBL432230; Regorafenib,BAY 73-4506; GTPL5891; orb1307437; orb3141308; SCHEMBL29349808; SCHEMBL29351376; EX-A058; GLXC-90063; HMS3654K16; HMS3672E15; HMS5079O11; BDBM50363397; EBC-11382; HY-10331R; NSC763932; NSC800865; s1178; AKOS015951107; CCG-269571; CS-0170; DB08896; FR16116; NSC-763932; NSC-800865; SB16819; SDCCGSBI-0654355.P001; NCGC00263138-01; NCGC00263138-13; NCGC00263138-18; NCGC00263138-19; AC-25075; AC-31116; AS-16304; BP-44042; HY-10331; Regorafenib for FP system suitability CRS; SMR004701370; NS00040710; R0142; R1627; SW218097-2; cas:835621-07-3;Regorafenib hydrochloride; Regorafenib (BAY73-4506,Fluoro-Sorafenib); D10138; Regorafenib (BAY73-4506,Fluoro-Sorafenib)?; AB01565826_02; F361865; SR-01000941571; Q3891664; SR-01000941571-1; BRD-K16730910-001-02-4; BRD-K16730910-001-07-3; Z2235801830; 4-[4-({[4-Chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide; 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamideSynonyme